Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy

BRCA2-loss CAPC displays a distinct genomic landscape, marked by robust HRD features, suggesting the potential of higher sensitivity to PARPi. These findings highlight the relevance of HRDsig, and routinely use of CGP in refining patient selection for PARPi and guiding the design of future clinical trials.